Therefore, substances that increase AQP3 expression by signaling pathways other than Ras/MAPK or substances that activate the Ras/MAPK pathway in a skin-specific manner would be effective for treatment or preventing erlotinib-induced dry skin. The gene discussed is AQP3; the disease is Dry skin.